Compounds > 4'-methylene-5,8,10-trideazaaminopterin
Page last updated: 2024-12-11

4'-methylene-5,8,10-trideazaaminopterin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4'-methylene-5,8,10-trideazaaminopterin: an antirheumatic agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9846537
CHEMBL ID4802141
SCHEMBL ID7281
MeSH IDM0500513

Synonyms (19)

Synonym
SCHEMBL7281
4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid
ch 1504
unii-8y3rh62xpb
mobiletrex
4'-methylene-5,8,10-trideazaaminopterin
238074-89-0
8y3rh62xpb ,
ch-1504
m-trex
DB05616
CHEMBL4802141
2-(4-(2-(2,4-diaminoquinazolin-6-yl)ethyl)benzamido)-4-methylenepentanedioic acid
2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid
glutamic acid, n-(4-(2-(2,4-diamino-6-quinazolinyl)ethyl)benzoyl)-4-methylene-
tridam
aa-243
2-((4-(2-(2,4-diaminoquinazolin-6-yl)ethyl)benzoyl)amino)-4-methylene-pentanedioic acid
AKOS040748126

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse events across treatment groups were mild."( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study.
Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011)		0.37
"CH-1504 has comparable efficacy to MTX and is safe and well tolerated."( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study.
Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011)		0.37

Pharmacokinetics

ExcerptReferenceRelevance
" However, the results of the pharmacokinetic analysis support the development of a new formulation to improve the bioavailability before further clinical studies are warranted."( Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
Adams, L; Boland, J; Hewitt, LA; Jurcevic, S; Mant, T; Szakacs, C, 2008)		0.35

Bioavailability

ExcerptReferenceRelevance
" However, the results of the pharmacokinetic analysis support the development of a new formulation to improve the bioavailability before further clinical studies are warranted."( Two single-center, double-blind, randomized, placebo-controlled, phase I studies to investigate the tolerability and pharmacokinetics of CH-1504, an antifolate, in healthy male subjects.
Adams, L; Boland, J; Hewitt, LA; Jurcevic, S; Mant, T; Szakacs, C, 2008)		0.35

Dosage Studied

ExcerptRelevanceReference
" No dose-response relationship was observed."( Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study.
Hewitt, LA; Keystone, EC; Pedder, S; Shirinsky, VS; Simon, LS, 2011)		0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.07 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (50.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1 (16.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methotrexate
[no description available]		5.3122dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
aminopterin
Aminopterin: A folic acid derivative used as a rodenticide that has been shown to be teratogenic.		8.1363dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
ConditionIndicatedRelationship StrengthStudiesTrials
Rheumatoid Arthritis
[description not available]		06.7442
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		18.7442
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		02.9810
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		02.9810
Dermatitis Medicamentosa
[description not available]		03.4311